USA flag logo/image

An Official Website of the United States Government

A Novel Tolerance Therapeutic to Treat Asthma

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43HL114214
Solicitation Year:
2012
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA11-096
Small Business Information
VIRTICI
454 N 34TH ST SEATTLE, WA 98103-8602
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: A Novel Tolerance Therapeutic to Treat Asthma
Agency: HHS
Contract: 1R43HL114214-01
Award Amount: $689,961.00
 

Abstract:

DESCRIPTION (provided by applicant): Approximately 22 million people in the US suffer from asthma (National Heart, Lung, and Blood Institute). As a result, the annual economic cost of asthma is 19.7 billion. Globally, an estimated 300 million people worldwide have asthma, with 250,000 annual deaths attributed to the disease, and the prevalence continues to increase. By 2025, the number of people with asthma is estimated to grow to more than 400 million. Asthma is a respiratory condition in which the airways become inflamed and constrict, usually in response to one or more environmental triggers. When an asthma attack occurs, the muscles surrounding the airways become constricted and the lining of the air passages swells, reducing the amount of air that canpass to the lungs. In highly asthmatic people, breathing in an allergic substance, or allergen, can induce symptoms. Current treatments for asthma are associated with blocking or inhibiting an asthma attack and subsequent air passage swelling. The most successful drugs on the market combine long-acting beta-agonists (LABAs) with steroids, and include Advair, Symbicort and Duleral. While these are somewhat effective at managing asthma symptoms, the effects are temporary, have many side-effects, and requiredaily administration. Desensitization protocols exist, but are intensive and impractical given the fact that most asthmatics have multiple, often unidentified, allergens. A natural therapeutic that promotes asthma regression through a clearly defined, novel mechanism would provide profound medical advancement in treatment of asthma. The goal of these studies is to advance a new tolerance-inducing therapeutic, called HH-10, toward the clinic to treat patients with asthma. Recently, we demonstrated that HH-10 acts as a tolerance-inducing therapeutic by promoting the induction of IL-10 producing regulatory T cells (TR1) from conventional antigen-specific memory T cells. The aims of the proposed studies are to: 1) confirm in an airway hypersensitivity mousemodel that inhaled administration of HH-10 regresses airway hypersensitivity and to identify the effective HH-10 dosing for future pre-clinical studies; and 2) examine potential in vivo toxicity and side-effects associated with HH-10 treatment, providing data that effective dosing concentrations demonstrate no or minimal side effects. PUBLIC HEALTH RELEVANCE: Current therapeutic treatments for asthma target symptoms. This project aims to develop a tolerance-inducing therapeutic that promotes asthmaregression through a novel mechanism. Success would ultimately provide a profound medical advancement in treatment of asthma, a significant benefit to human health, and a dramatic reduction in the economic impact of asthma in the US and globally.

Principal Investigator:

Neil A. Fanger
206-228-1458
nfanger@virtici.com

Business Contact:

Neil Fanger
206-228-1458
nfanger@virtici.com
Small Business Information at Submission:

VIRTICI
454 N 34TH ST SEATTLE, WA 98103-8602

EIN/Tax ID: 127516330
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No